Safety and Efficacy Study of SAR 1118 to Treat Dry Eye
The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%)
compared to placebo in the treatment of Dry Eye. The safety and tolerability of SAR 1118
Ophthalmic Solution (5.0%) compared to placebo in subjects with dry eye when administered
BID for 12 weeks will also be evaluated.
The purpose of the study is to evaluate the safety of lifitegrast ophthalmic solution
compared to placebo in the treatment of dry eye as assessed by ocular and non-ocular adverse
events when administered BID for approximately 1 year.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.